Advertisement

Oxaliplatin und CPT-11 sind wirksam in der Prävention jedoch nicht in der Behandlung experimentell erzeugter Peritonealkarzinomatose

  • F. Meyer
  • Arndt Hribaschek
  • H. Lippert
  • K. Ridwelski
Conference paper
Part of the Deutsche Gesellschaft für Chirurgie book series (DTGESCHIR, volume 31)

Abstract

After surgical resection of colorectal carcinoma, the high local recurrence rate at the original tumor or the peritoneal site remains an unsolved problem. Currently, there are no established standardized therapy protocols for the prevention or treatment of peritoneal carcinomatosis. CPT-11 and Oxaliplatin are novel cytostatic agents, which can provide beneficial effects in the treatment of patients with advanced colorectal cancer. The aim of our study was to investigate whether these substances can inhibit intraperitoneal (i. p.) tumor growth using a rat model of experimental carcinomatosis. Animals were devided into three groups including controls. In group 1, antineoplastic agents were administered directly into the peritoneal cavity following tumor cell transfer, whereas in group 2, substances were given as early postoperative i.p. chemotherapy (d5, 10 & 15 after cell transfer) via port-a-cath. Group 3: i.p. chemotherapy (15 d interval after cell transfer) was administered with the intention of reducing a manifest peritoneal carcinomatosis. The results indicated that CPT-11 and Oxaliplatin were significantly effective in reducing intraperitoneal tumor growth after direct i.p. application during laparotomy for tumor cell transfer. In addition, i.p. administration of CPT-11 or Oxaliplatin also inhibited tumor growth using short postoperative intervals of i.p. chemotherapy. However, the chemotherapeutic protocol was not effective after manifestation of peritoneal carcinomatosis, showing that 1) CPT-11 and Oxaliplatin are potential agents for this setting and 2) it appears to be essential to focus on early administration of chemotherapy in particular for prevention of peritoneal carcinomatosis.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Benoit L, Duvillard C, Beltramo JL, Brunet-Lecomte P, Chauffert B (2000) Intraperitoneal cisplatin plus epinephrine and surgical debulking for the treatment of advanced peritoneal carcinomatosis in the rat. Gastroenterol Clin Biol 24: 26 – 30PubMedGoogle Scholar
  2. 2.
    Maruyama M, Takamatsu S, Sugano N, Ebuchi M, Endo M, Yuasa Y (1997) Experimental Study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration. Gan To Kagaku Yoho 24: 2131 –2136Google Scholar
  3. 3.
    Aparicio T, Kermorgant S, Dessirier V, Lewin MJ, Lehy T (1999) Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 20: 1445–1451PubMedCrossRefGoogle Scholar
  4. 4.
    Hotz HG, Reber HA, Hotz B et al. (2001) Angiogenesis inhibtor TNP reduces human pancreatic cancer growth. J Gastrointest Surg 5: 131–138PubMedCrossRefGoogle Scholar
  5. 5.
    Shiu M, Fortner J (1980) Intraperitoneal hyperthermic treatment of implantated peritoneal cancer in rats. Cancer Res 40: 4081–4048PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • F. Meyer
    • 1
  • Arndt Hribaschek
    • 1
  • H. Lippert
    • 1
  • K. Ridwelski
    • 2
  1. 1.Klinik für ChirurgieOtto-von-Guericke-UniversitätMagdeburgGermany
  2. 2.Klinik für ChirurgieStädtisches Klinikum, DessauGermany

Personalised recommendations